Editor's note: After a distinguished career in academic medicine, including stints at the Children's Hospital of Philadelphia, INSERM and Genethon, Federico Mingozzi joined Spark Therapeutics 3 years ago as chief scientific officer. Mingozzi aims to build on the company's landmark success with Luxturna, the approved therapy for certain retinal diseases such as the type 2 version of Leber's congenital amaurosis. In this exclusive interview with Human Gene Therapy Executive Editor Kevin Davies, Mingozzi discusses his career highlights and surveys the hopes and challenges facing the human gene therapy community.

中文翻译：

---

意大利工作：专访费德里科·明戈齐

编者按：在学术医学领域的杰出职业生涯之后，包括在费城儿童医院、INSERM 和 Genethon 工作，Federico Mingozzi 于 3 年前加入 Spark Therapeutics，担任首席科学官。Mingozzi 的目标是在公司与 Luxturna 取得里程碑式成功的基础上再接再厉，Luxturna 是某些视网膜疾病的批准疗法，例如 2 型 Leber 先天性黑蒙。在对人类基因治疗执行编辑 Kevin Davies 的独家采访中，Mingozzi 讨论了他的职业亮点并调查了人类基因治疗社区面临的希望和挑战。